Zydus Lifesciences
Zydus Lifesciences, formerly known as Zydus Cadila, is a prominent player in the global pharmaceutical industry, headquartered in India. Founded in 1995, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Zydus Lifesciences focuses on research and development, manufacturing, and marketing of a diverse range of healthcare products, including generic medicines, biosimilars, and vaccines. With a commitment to innovation, Zydus Lifesciences has achieved significant milestones, such as the development of India's first indigenously produced DNA vaccine. The company is recognised for its robust portfolio of over 1,000 products, which cater to various therapeutic areas, making it a key player in the pharmaceutical market. Zydus Lifesciences continues to enhance its market position through strategic partnerships and a dedication to improving global health outcomes.
DitchCarbon Score
How does Zydus Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zydus Lifesciences's score of 40 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zydus Lifesciences's reported carbon emissions
In 2024, Zydus Lifesciences reported total carbon emissions of approximately 307,413,650 kg CO2e, comprising 67,705,110 kg CO2e from Scope 1, 239,708,530 kg CO2e from Scope 2, and 24,393,000 kg CO2e from Scope 3. This data reflects a comprehensive approach to emissions reporting, with all three scopes disclosed. For the previous year, 2023, the company recorded emissions of about 9,928,000 kg CO2e from Scope 1 and 3,490,000 kg CO2e from Scope 2 in India, while globally, the figures were approximately 56,053,320 kg CO2e for Scope 1, 223,014,700 kg CO2e for Scope 2, and 25,670,000 kg CO2e for Scope 3. Zydus Lifesciences has committed to achieving carbon neutrality in its operations (Scope 1 and 2 emissions) by FY2035. This long-term target demonstrates the company's dedication to reducing its carbon footprint and aligns with industry standards for climate action. The company is also classified as "Committed" to net-zero targets, indicating a proactive stance in addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zydus Lifesciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
